Tuesday, August 11, 2009

Human Genome Sciences (NASDAQ:HGSI): New Street high target from Leerink Swann

Leerink Swann is out very positive on Human Genome Sciences (NASDAQ:HGSI) raising their 12-month target on the name to $30 (prev $16).

Bottom Line: Leerink's statistical power analysis confirms an ~85% likelihood of success for BLISS-76 data in November. They considered the major factors which could influence p-value via effect size and variability in the context of past results for Benlysta in BLISS-52 and Phase II. Reiterate Outperform, raising 12-month fair value to $30 from $16.

As shown by the tables within, 67 of the 80 (84%) most likely combinations of response rates and standard deviation included in Leerink's sensitivity analysis would produce statistically significant (p<0.05). They believe BLISS-76 has been derisked after BLISS-52 results since the major difference between the two trials is geography, and the patient population in BLISS-76 (US & EU) is more similar to the Phase II trial which was data mined in order to design Phase III.

An 8% response rate delta between Benlysta and placebo on the primary endpoint would be statistically significant in BLISS-76 if the same standard deviation as seen in BLISS-52 occurs.
Furthermore, a 9% delta would be sufficient at all standard deviations analyzed. Recall that Phase III (10mg/kg), Phase III (1mg/kg), and Phase II showed deltas of 14%, 8%, and 17%, respectively. At the lowest standard deviation analyzed, even a 6% delta in response rates would achieve a p=0.042.

Standard deviation should not be that different in BLISS-76 as compared to BLISS-52. HGSI appears to have done a good job controlling for most of the factors which may cause variability, judging by the consistent standard deviations seen in Phase II and BLISS-52.
On the one hand, lupus patients in North America and Western Europe (BLISS-76) may be more uniformly treated than in Asia, Latin America and Eastern Europe (BLISS-52); however, this may be offset by more genetic heterogeneity in the BLISS-76 population vis a vis BLISS-52.

Placebo response rate could be lower in BLISS-76, allowing an easier separation in the curves due to effect size.
Studies done in the U.S. and Western Europe frequently show less of a placebo effect due to better care overall and less pronounced effect from entering studies.

$30 from Leerink Swann is the new Street high for the stock. This should send the stock higher, testing for another breakout following ThinkEquity's upgrade a week ago. It's quite clear positive momentum ahead of the BLISS-76 data release in November is building.

Now that Leerink Swann, one the premier biotech houses is calling the trial a ~ 85% success, the stock should take off from here. Note that by many, Leerink is considered to be the Axe in HGSI.

Leerink was very positive on HGSI ahead of the BLISS-52, which sent the shares up 500% (!) in the March-July timeframe.

I suspect the stock will trade over $15 level today...reaching $15.50 (again) and possibly surpassing it.

Nice job Leerink!


lowsignal said...

It looks like the good news made premarket. It's at 16.50

alotstuff said...

nice blog and have lots of stuff here.........


cute said...

nice blog and have lots of stuff here.........Human Genome